Alkermes plc (NASDAQ:ALKS) Stake Lowered by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC trimmed its position in shares of Alkermes plc (NASDAQ:ALKS) by 11.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,767 shares of the company’s stock after selling 3,047 shares during the period. Mutual of America Capital Management LLC’s holdings in Alkermes were worth $693,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of ALKS. V Square Quantitative Management LLC bought a new stake in Alkermes during the third quarter valued at about $29,000. Signaturefd LLC increased its stake in shares of Alkermes by 51.2% in the second quarter. Signaturefd LLC now owns 1,417 shares of the company’s stock worth $34,000 after purchasing an additional 480 shares during the period. Hexagon Capital Partners LLC lifted its position in shares of Alkermes by 3,841.0% during the 2nd quarter. Hexagon Capital Partners LLC now owns 1,537 shares of the company’s stock worth $37,000 after purchasing an additional 1,498 shares during the last quarter. GAMMA Investing LLC boosted its stake in Alkermes by 44.4% during the 2nd quarter. GAMMA Investing LLC now owns 2,287 shares of the company’s stock valued at $55,000 after purchasing an additional 703 shares during the period. Finally, Ashton Thomas Private Wealth LLC acquired a new stake in Alkermes in the 2nd quarter valued at approximately $116,000. Institutional investors and hedge funds own 95.21% of the company’s stock.

Alkermes Stock Performance

Shares of Alkermes stock opened at $29.25 on Wednesday. The stock has a market cap of $4.73 billion, a price-to-earnings ratio of 15.00, a P/E/G ratio of 0.96 and a beta of 0.47. Alkermes plc has a twelve month low of $22.22 and a twelve month high of $32.88. The company’s fifty day moving average is $27.95 and its 200 day moving average is $26.45. The company has a quick ratio of 3.03, a current ratio of 3.45 and a debt-to-equity ratio of 0.22.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. Piper Sandler reaffirmed an “overweight” rating and set a $37.00 target price (down previously from $38.00) on shares of Alkermes in a research report on Friday, October 25th. Cantor Fitzgerald dropped their price objective on shares of Alkermes from $48.00 to $43.00 and set an “overweight” rating on the stock in a report on Friday, October 25th. Stifel Nicolaus upgraded shares of Alkermes from a “hold” rating to a “buy” rating and increased their target price for the company from $25.00 to $36.00 in a research note on Tuesday, November 5th. Mizuho lifted their target price on Alkermes from $35.00 to $40.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. Finally, HC Wainwright reaffirmed a “neutral” rating and issued a $37.00 price target on shares of Alkermes in a report on Friday, October 25th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, Alkermes has an average rating of “Moderate Buy” and a consensus target price of $35.42.

Insider Buying and Selling

In related news, EVP Craig C. Hopkinson sold 10,471 shares of the company’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $29.53, for a total transaction of $309,208.63. Following the transaction, the executive vice president now directly owns 99,238 shares of the company’s stock, valued at approximately $2,930,498.14. This represents a 9.54 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.89% of the stock is owned by insiders.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.